KD Logo

Analysts review Theravance Biopharma Inc’s rating

Theravance Biopharma Inc’s filing revealed that its SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda unloaded Company’s shares for reported $36000.0 on Jul 10 ’24. In the deal valued at $9.00 per share,4,000 shares were sold. As a result of this transaction, Farnum Rhonda now holds 335,965 shares worth roughly $2.63 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Samaha Eli bought 1,499,124 shares, generating $13,117,335 in total proceeds. Upon buying the shares at $8.75, the 10% Owner now owns 8,511,350 shares.

Before that, Farnum Rhonda sold 1,254 shares. Theravance Biopharma Inc shares valued at $10,922 were divested by the SVP, COMM & MEDICAL AFFAIRS at a price of $8.71 per share. As a result of the transaction, Farnum Rhonda now holds 311,733 shares, worth roughly $2.44 million.

Leerink Partners downgraded its Theravance Biopharma Inc [TBPH] rating to a Market perform from a an Outperform in a research note published on August 06, 2024; the price target was decreased to $10 from $15. A number of analysts have revised their coverage, including BTIG Research’s analysts, who began to cover the stock in mid April with a ‘”a Buy”‘ rating. Evercore ISI also remained covering TBPH and has decreased its forecast on January 08, 2024 with a “an In-line” recommendation from previously “an Outperform” rating. SVB Leerink started covering the stock on May 23, 2022. It rated TBPH as “an Outperform”.

Price Performance Review of TBPH

On Tuesday, Theravance Biopharma Inc [NASDAQ:TBPH] saw its stock fall -18.35% to $7.83. Over the last five days, the stock has lost -22.17%. Theravance Biopharma Inc shares have fallen nearly -30.34% since the year began. Nevertheless, the stocks have fallen -21.31% over the past one year. While a 52-week high of $11.71 was reached on 01/04/24, a 52-week low of $8.13 was recorded on 08/06/24. SMA at 50 days reached $9.05, while 200 days put it at $9.48. A total of 1.97 million shares were traded, compared to the trading of 0.36 million shares in the previous session.

Levels Of Support And Resistance For TBPH Stock

The 24-hour chart illustrates a support level at 7.29, which if violated will result in even more drops to 6.74. On the upside, there is a resistance level at 8.78. A further resistance level may holdings at 9.72. The Relative Strength Index (RSI) on the 14-day chart is 27.29, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.79, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.87%. Stochastics%K at 16.97% indicates the stock is a buying.

Most Popular